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Abstract
The epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in Africa is poorly documented. From January 2007 to March 2008,
we collected 86 MRSA isolates from ﬁve African towns, one each in Cameroon, Madagascar, Morocco, Niger and Senegal. Although one
or two major clones, deﬁned by the sequence type and staphylococcal cassette chromosome mec type, predominated at each site, genetic
diversity (ten clones) was relatively limited in view of the large geographical area studied. Most of the isolates (n = 76, 88%) belonged to
three major clones, namely ST239/241-III, a well-known pandemic clone (n = 34, 40%), ST88-IV (n = 24, 28%) and ST5-IV (n = 18, 21%).
The latter two clones have only been sporadically described in other parts of the world. The spread of community-associated MRSA car-
rying the Panton–Valentine leukocidin genes is a cause for concern, especially in Dakar and possibly throughout Africa.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) strains have
spread throughout the world, ﬁrst in the hospital setting and
more recently in the community. Only ﬁve major ancestral
hospital clones of MRSA are recognized, suggesting that
acquisition of the staphylococcal cassette chromosome
(SCC)mec, the genetic element harboring the mecA gene that
confers methicillin resistance, has been a rare event. Most
hospital-associated MRSA (HA-MRSA) clones are found
worldwide, although their frequencies vary from country to
country. For example, the major HA-MRSA clone (Lyon)
found in France is neither dominant nor even frequent in
neighboring countries [1].
Initially, community-associated MRSA (CA-MRSA) differed
from HA-MRSA by their continental distribution but travel
has rapidly blurred this distinction. For example, the
CA-MRSA clone USA300, initially restricted to the USA, is
now detected in many other countries [2], albeit at a low
frequency. Likewise, all the most common CA-MRSA clones
(USA 300, the European sequence type (ST) 80 clone and
the Oceania ST30 clone) have been detected in Singapore, a
major intercontinental travel hub [3]. Almost a quarter of a
century elapsed between the emergence of MRSA in indus-
trialized countries in the 1960s and its ﬁrst description in
Africa in 1988 [4]. However, data on the epidemiology of
MRSA in Africa remain scarce [5–9].
We collected MRSA isolates from ﬁve major African
towns in Morocco (North Africa), Senegal (West Africa),
Niger (West Africa), Cameroon (Central Africa) and
Madagascar (East Africa), and performed accessory gene
regulator (agr) typing, multilocus sequence typing (MLST),
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staphylococcal protein A (spa) typing, and toxin proﬁling.
Antimicrobial susceptibility was also evaluated.
Materials and methods
Study population
All patients with suspected staphylococcal infection were
pre-included in seven major tertiary care centres located in
ﬁve major African towns, namely Antananarivo (Madagascar),
Casablanca (Morocco), Niamey (Niger), Dakar (Senegal) and
Yaounde (Cameroon), between January 2007 and March
2008 (January 2007 to June 2007 in Casablanca). They were
included in the study only if their S. aureus isolate was con-
ﬁrmed to be resistant to methicillin. A standardized speciﬁc
medical record was ﬁlled out during the hospitalization. If
more than one S. aureus isolate with the same toxin type
was recovered from the same patient, only the ﬁrst was
included. Isolates were considered to be community-acquired
if recovered by culture from a sample obtained within 48 h
after admission in a patient with no risk factors for nosoco-
mial acquisition in the previous year, namely hospitalization
or surgery, use of an indwelling catheter or a percutaneous
device, or frequent exposure to healthcare facilities for an
underlying chronic disorder. All other isolates were consid-
ered hospital-acquired. The study protocol was approved by
local ethics committees.
Microbiological analysis
S. aureus identiﬁcation was based on Gram staining, morphol-
ogy, catalase positivity (ID color Catalase; bioMe´rieux, Marcy
l’Etoile, France), agglutination in the Pastorex Staph Plus
test (Bio-Rad, Marnes la Coquette, France) and free coagu-
lase production (lyophilized rabbit plasma; bioMerieux).
DNA extraction, mecA detection, agr typing and SCCmec
typing
Genomic DNA was extracted with a standard phenol–chlo-
roform procedure [10]. Species identiﬁcation was conﬁrmed
by multiplex PCR ampliﬁcation of the agr locus [10], allowing
concomitant determination of the agr allelic group. All iso-
lates were screened for genes encoding methicillin resistance
(mecA), staphylococcal enterotoxins (se) A, B, C, D, H, K, L,
M, O, P, Q, and R (sea-d, seh, sek-m, seo-r), toxic shock syn-
drome toxin 1 (tst), exfoliative toxins A, B and D (eta, etb,
etd), Panton–Valentine leukocidin (luk-PV), class F LukM leuk-
ocidin (lukM), b-haemolysin (hlb) and epidermal cell differen-
tiation inhibitor (edinA/B/C), as previously described [10,11].
SCCmec types were determined by PCR with a simpliﬁed
version of Kondo’s typing system, including M-PCR-1 and
M-PCR-2, without considering the structure of the junkyard
region [12].
Spa typing and MLST
Spa sequence typing was performed with the Ridom Staph
Type standard protocol (http://www.3.ridom.de.doc/Ridom_
spa_sequencing.pdf) and the Ridom SpaServer, which auto-
matically analyzes spa repeats and assigns spa types (http://
spa.ridom.de/index.shtml). MLST was performed as described
previously [13]. MLST and spa typing were performed on 23
representative isolates of all toxin types within each agr type.
Antimicrobial susceptibility
Susceptibility to penicillin, oxacillin, cefoxitin, gentamicin,
kanamycin, tobramycin, tetracycline, erythromycin, lincomy-
cin, pristinamycin, fosfomycin, fusidic acid, rifampicin, peﬂoxa-
cin, co-trimoxazole and vancomycin was determined by each
participating laboratory, in accordance with the guidelines of
the French Society for Microbiology [14]. S. aureus strain
ATCC 25923 was used for quality control. External quality
control was ensured by the French National Antibiotic Ref-
erence Center (Pasteur Institute, Paris, France).
Results and Discussion
In total, 542 patients were included during the study period.
Six hundred and nine biological samples were taken and 555
S. aureus strains were collected, of which 86 were resistant
to methicillin. The low prevalence of MRSA (15%), combined
with the lack of systematic samples for bacteriological culture
and frequent initiation of antibiotic therapy before biological
sampling, explains the small number of MRSA isolates. Never-
theless, this represents the largest collection of clinical MRSA
isolates ever studied on the African continent, excluding
Nigeria and South Africa. Isolates were recovered mainly
from male patients (64%). The patients’ median age was
29.0 years (mean 32.4 years; range 2 months to 84 years).
Nine isolates (10%) were recovered in Yaounde (Cameroon),
11 (13%) in Niamey (Niger), 16 (19%) in Antananarivo (Mada-
gascar), 21 (24%) in Casablanca (Morocco) and 29 (34%) in
Dakar (Senegal) (Fig. 1). Forty-four isolates (51%) were asso-
ciated with skin and soft-tissue infections, 27 (31%) with sur-
gical wound infections, nine (10%) with bacteraemia/
septicaemia, four (5%) with urinary/genital tract infections
and two (2%) with osteomyelitis/myositis. The small number
of isolates associated with bacteraemia/septicaemia reﬂects
the lack of routine blood culture in the participating centres.
The 86 isolates belonged to seven STs and ﬁve clonal
complexs (CCs). The isolates were assigned to ten different
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clones according to their sequence type and SCCmec type.
Most of the isolates (n = 76, 88%) belonged to only three
major clones, namely ST239/241-III (n = 34, 40%), ST88-IV
(n = 24, 28%) and ST5-IV (n = 18, 21%) (Table 1).
The ﬁrst major clone (34 isolates, 40%) was related to the
Brazilian/Hungarian one, a well-known HA-MRSA clone of
CC239 with the following characteristics: ST239 or ST241,
agr 1, SCCmec type III and spa-type t037 or related [15].
This clone was detected in three of the ﬁve towns, namely
Casablanca (n = 20, 59%), Dakar (n = 8, 24%) and Niamey
(n = 6, 18%). It was the dominant clone in Casablanca (95%
of all MRSA isolates from this site) and Niamey (55%)
(Table 1).
The sek and selq genes were detected in all the isolates
belonging to this clone, whereas the sea and selp genes were
present in only 38% and 21% of such isolates, respectively.
Isolates belonging to this clone were all resistant to kanamy-
cin, tobramycin, gentamicin, tetracycline and peﬂoxacin
(Table 2). This clone has already been extensively described
as a major clone in many countries in Asia, Europe and
South America [15]. The results obtained in the present
study, together with data from Algeria [9] and Nigeria [6],
suggest that this pandemic multidrug-resistant clone is also
spreading in Africa.
The second major clone accounted for 24 (28%) of the 86
isolates. Unexpectedly, it was ST88-IV, agr 3 and spa-type
t186 or related (except for one isolate that was spa-type
t168). The only toxin genes present in these isolates were
hlb (n = 2) and eta (n = 8). Antimicrobial susceptibility was
highly variable (ten different antibiotypes), but was mainly
characterized by resistance to methicillin and susceptibility to
aminoglycosides (92%) and ﬂuoroquinolones (96%). ST88-IV
has not previously been described as an epidemic MRSA
clone; it has been reported only sporadically and in very few
FIG. 1. The distribution of methicillin-resistant Staphylococcus aureus
(MRSA) clones, each deﬁned by their sequence type (ST) followed
by their staphylococcal cassette chromosome mec type, in ﬁve Afri-
can towns (Antananarivo, Casablanca, Dakar, Niamey and Yaounde).
The proportions of clones at each sampling location are displayed as
pie charts, with size indicating the number of isolates (red numbers).
TABLE 1. Molecular characteristics of CA-MRSA and HA-MRSA isolates recovered in ﬁve African towns (Antananarivo,






(no.) Toxin genes (no.)
HA-MRSA (n = 77) CA-MRSA (n = 9)
Location (n) Total Location (n) Total
239 ST239/241-agr1
SCCmec III t037 (29)
t138 (5)
sek (34), selq (34)
sea (13), selp (7)
C (20), D (8),
N (6)
34
SCCmec V t037 (1) sea (1), sek (1), selq (1) N (1) 1
88 ST88-agr3
SCCmec IV t168 (1)
t186 (15)
t729 (8)
eta (9), hlb (2) A (10), D (1),
N (5), Y (4)
20 A (3), D (1) 4
SCCmec V t729 (1) A (1) 1
ST1289-agr3
SCCmec IV t1339 (1) eta (1), sem (1), seo(1), luk-PV (1) Y (1) 1
5 ST5-agr2
SCCmec II t311 (2) sem (2), seo (2), luk-PV (2), edin A/B/C (2) D (2) 2
SCCmec IV t311 (18) seb (1), selq (1), sem (18), seo (18), luk-PV (17), edin A/B/C (13) D (13), C (1) 14 D (4) 4
SCCmec V t311 (1) seb (1), selq (1), sem (1), seo (1), luk-PV (1), edin A/B/C (1), hlb (1) Y (1) 1
8 ST8-agr1
SCCmec IV t121 (1)
t451 (1)
t024 (1)
sea (2), seb (1), sek (1), luk-PV (1) A (1), Y (2) 3 Y (1) 1
30 ST30-agr3
SCCmec V t4686 (1) seb (1), sem (1), seo (1), selp (1) A (1) 1
CA-MRSA, community-associated methicillin-resistant Staphylococcus aureus; HA-MRSA, hospital-associated methicillin-resistant Staphylococcus aureus; ST, sequence type; agr,
accessory gene regulator; SCCmec, staphylococcal cassette chromosome mec; spa, staphylococcal protein A; edin, epidermal cell differentiation inhibitor; eta, exfoliatin A; etb,
exfoliatin B; etd, exfoliatin D; hlb, b-haemolysin; luk, staphylococcal leukocidin; se, staphylococcal enterotoxin; tst, toxic shock syndrome toxin; A, Antananarivo; C, Casablanca;
D, Dakar; N, Niamey; Y, Yaounde.
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countries, including one isolate each in Belgium [16] and
Portugal [17], as well as ten isolates in Sweden [18]. By con-
trast, this clone was detected in all the participating centres
in the present study, apart from Casablanca, and was the
predominant clone in Antananarivo (n = 13, 81%), Niamey
(n = 5, 45%) and Yaounde (n = 4, 44%). The high prevalence
of this clone in Africa is conﬁrmed by reports of its recent
detection in Nigeria [5], as well as in children from Western
Africa who had surgery in Switzerland and had been hospital-
ized in their home countries [19]. Furthermore, this clone
appeared to be present in both the community and hospital
settings in Antananarivo and Dakar. All these ﬁndings cause
concern because they highlight: (i) the ability of this clone to
spread over a large geographic area, including Central, East
and West Africa, and (ii) the potential role of the African
continent as a reservoir for this clone. Moreover, two iso-
lates, one of ST88-V and spa-type t729 lacking toxin genes,
and one of ST1289-IV (a single-locus variant of ST88) and
spa-type 1339 associated with eta plus the luk-PV genes, clus-
tered in the same clonal complex, CC88, and corresponded
to none of the previously described clones. The emergence
of a clone harboring both eta (involved in staphylococcal
scalded-skin syndrome and bullous impetigo) [20] and luk-PV
(able to induce necrotizing syndromes) [21] genes is a major
concern.
The third major clone, ST5-IV (n = 18, 21%), was recov-
ered once in Casablanca (Morocco), whereas the remaining
isolates were all from Dakar, Senegal, where this clone pre-
dominated (17 of 29 isolates, 59%). These isolates possessed
an agr2 allele and were all assigned to spa type t311. They
were susceptible to most antibiotics, with the noteworthy
exceptions of tetracycline (83% resistant) and cotrimoxazole
(89% resistant). Their toxin genes included sem and seo, usu-
ally associated with luk-PV (n = 17, 94%) and edin A/B/C
(n = 13, 72%).
These characteristics match the molecular and phenotypic
features of CA-MRSA. The Panton–Valentine leukocidin (PVL)-
positive ST5-IV isolates were from 17 patients (male:female
ratio 0.59, median age 35.0 years, mean age 32.7 years, range
2 months to 58 years) with skin and soft-tissue infections
in nine cases, surgical wound infections in six cases and
bacteraemia/septicaemia and osteomyelitis in one case each.
Thirteen (76%) of the 17 infections were hospital-acquired.
The presence of luk-PV in MRSA with the ST5 genetic back-
ground is uncommon and of particular concern because:
(i) several pandemic clones (New York/Japan and Pediatric
clones) associated with the ST5 genetic background have
shown strong epidemic potential in hospital settings; (ii) the
SCCmec IV cassette, a small genetic element, does not have a
biological ﬁtness cost and allows stable populations of MRSA
to emerge [22]; and (iii) the luk-PV genes encoding PVL, a
major virulence factor, are associated with skin and soft-tissue
infections and also with severe necrotizing pneumonia [21,23].
Recently, such community-acquired ST5-IV MRSA isolates
harboring PVL genes have been reported sporadically in
Algeria, France, Switzerland, Ireland and Slovenia, and have
started to emerge in healthcare settings in Argentina [24–27].
Further studies are needed to evaluate their spread through
Africa and its genetic and epidemiological links with previously
described ST5-IV isolates.
We identiﬁed two other infrequent clones (ST5-II, n = 2
and ST5-V, n = 1), which, interestingly, harbored the luk-PV
gene and also clustered within CC5. PVL genes are carried
on a prophage, implying that these genes could have been
incorporated into S. aureus lineages through horizontal trans-
fer, either before or after the acquisition of mecA gene.
Alternatively, these clones could illustrate genetic recombina-
tion involving the SCCmec cassette.
Finally, we identiﬁed some sporadic clones, such as ST8-IV
(three isolates in Yaounde and one in Antananarivo) belong-
ing to CC8, and ST30-V (one isolate in Antananarivo)
belonging to CC30.
In the last decade, CA-MRSA, which are epidemiologically
and genetically different from HA-MRSA [28], have presented
a growing challenge in terms of its pathogenicity and antimi-
crobial resistance. Many data have been published on the
temporal and geographic dynamics of CA-MRSA in industrial-
ized countries. Our ﬁndings suggest that Africa is not exempt
from these trends and is also seeing the emergence and
spread of PVL-positive MRSA clones (n = 20, 23% of all
TABLE 2. Susceptibility pattern of the three major methicillin-resistant Staphylococcus aureus clones identiﬁed
ST-SCCmec
Non-b-lactam drug susceptibility
Always resistant (n) Variably resistant (n)
ST88-SCCmec IV (n = 24) KAN (1), TOB (1), ERY (10), LIN (1), TET (18), RIF (9), SXT (15)
ST5-SCCmec IV (n = 18) KAN (4), TOB (4), GEN (4), PEF (1), TET (15), SXT (16)
ST239/241-SCCmec III (n = 34) KAN, TOB, GEN, PEF, TET ERY (25), LIN (14), RIF (20), FOS (1), FU (12), SXT (24)
ST, sequence type; SCCmec, staphylococcal cassette chromosome mec; KAN, kanamycin; TOB, tobramy cin; GEN, gentamicin; ERY, erythromycin; LIN, lincomycin; PEF, pe-
ﬂoxacin; TET, tetracycline; RIF, rifampicin; FOS, fosfomycin; FU, fusidic acid; SXT, co-trimoxazole.
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isolates) carrying SCCmec cassette type IV or V and suscep-
tible to most antibiotics other than b-lactams [28]. As most
of these isolates (n = 16, 80%) were detected in Dakar
(Senegal), further investigations are needed to assess the
spread of such clones in other African countries.
We identiﬁed four different lineages corresponding to
CA-MRSA types, namely ST5-IV (n = 17), ST5-V (n = 1),
ST8-IV (n = 1) and ST1289-IV (n = 1) (a ﬁfth PVL-positive
clone, ST5-II, was detected but did not share features of
CA-MRSA). These four lineages were found in Dakar
(Senegal), Yaounde (Cameroon) and Casablanca (Morocco).
The successful PVL-positive CA-MRSA clone, ST80-SCCmec
IV described in Algeria [9], was not detected in the present
study. A large proportion of the isolates investigated in the
present study (n = 16, 80%) were recovered from patients
considered to have hospital-acquired infections, although this
must be interpreted with caution. First, deﬁnitions based on
time after hospital admission and care-associated risk factors
may underestimate the importance of the CA-MRSA reser-
voir, particularly in African hospitals where patients are not
systematically sampled for bacteriological culture within the
ﬁrst 48 h after admission as a result of organizational prob-
lems. However, molecular typing methods are often useful
for deﬁning CA-MRSA strains [29]. Second, when their prev-
alence in the community is high, CA-MRSA clones are able
to spread into hospitals [29]. Unfortunately, we did not
study the MRSA community reservoir in these African towns
and we cannot exclude the possibility that the PVL-positive
ST5-IV clone, mainly found in Dakar, could have emerged
locally in the hospital setting rather than in the community.
To test this hypothesis, further studies are needed to deter-
mine the prevalence and molecular characteristics of MRSA
clones in the community in Senegal. Third, few African hospi-
tals (except in North Africa and South Africa) are able to
implement all the measures required to prevent nosocomial
infections (i.e. measures that also act as a barrier between
the community and hospital settings), such as isolation of
infected patients, stringent hand hygiene, cleaning and disin-
fection of environmental surfaces, sterilization of medical
materials, and standard precautions during care procedures
(hand washing, gloves, mask, gown, linen and environmental
control). Fourth, the permanent presence of friends and
relatives in African hospitals, who share some healthcare
responsibilities for these patients, increases the risk of
MRSA circulation between the community and hospital
settings [30].
We studied 86 isolates from only one or two centres in
each country, which may not be representative of the global
situation. However, the present study provides an overview
of MRSA clones currently circulating in seven hospitals in ﬁve
major African towns, and is the ﬁrst of its type and scale.
The small number of isolates may also reﬂect the relatively
low incidence of MRSA infection in Africa. The healthcare
institutions studied were among the major tertiary hospitals
in each country. Although we found one or two predomi-
nant MRSA clones in each country, as classically reported in
Europe, the clonal diversity was somewhat limited for such a
large geographical area. However, given the small number of
MRSA isolates recovered at each site, the absence of certain
clones in this collection does not rule out their presence.
Although the major clone identiﬁed here is a well-known
pandemic clone (ST239/241-III), the distribution of the other
major clonal lineages (ST88-IV, ST5-IV) is very different from
that seen elsewhere in the world.
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